Panakeia to present results of blinded multi-site validation of its AI-driven molecular profiling tool for colon cancer, PANProfiler Colon, at ASCO GI Symposium
PANProfiler Colon achieved 92.69% positive and 94.05% negative agreement for MSI/dMMR detection Real-world blinded validation on 3178 colorectal cancer patient samples Data to be presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Cambridge, UK, 21 January 2025 – Panakeia (“the Company”), a pioneer in AI-driven multi-omic biomarker profiling, today announces it […]